Zobrazeno 1 - 10
of 60
pro vyhledávání: '"59"'
Autor:
L. Abdelmoula, H. Sahli Ep Hedi, R. Khalfallah, I. Mahmoud, Olfa Saidane, Rawdha Tekaya, A. Bachali
Publikováno v:
Annals of the Rheumatic Diseases. 75:849.2-849
Background Septic arthritis (SA) is an infection of synovial tissue that can affect one or more joints in patients of any age. It is considered as a medical and therapeutic emergency. Diagnosis is based on the presence of a microorganism in joint asp
Publikováno v:
Annals of the Rheumatic Diseases. 79:396.1-397
Background:While salivary gland ultrasound (SGUS) has widely used for evaluating Sjögren’s syndrome, information on SGUS findings of systemic sclerosis (SSc) is limited.Objectives:We aimed to evaluate the salivary gland involvement in patients wit
Publikováno v:
Annals of the Rheumatic Diseases. 79:1388.1-1389
Background:New medications including biologics and aggressive treatment strategies can halt the inflammatory and destructive disease processes in patients with rheumatoid arthritis (RA), and in some cases repair damaged joints. In the process of dama
Publikováno v:
Annals of the Rheumatic Diseases. 79:1754.3-1754
Background:Patients with juvenile dermatomyositis (JDM) are at risk of developing low bone mineral density (BMD) and not reach peak bone mass, mainly due to prednisolone (pred) treatment [1], making them prone to osteoporotic fractures later in lifeO
Autor:
Bernard Lauwerys, I Kone-Paut, Karine Lheritier, NM Wulffraat, M. Trachana, Vyacheslav Chasnyk, Pierre Quartier, S. Padeh, Hermine I. Brunner, E. Nasonov, A Martini, Tilmann Kallinich, Katherine Marzan, K. Leon, Daniel J. Lovell, Tamás Constantin, A. Speziale, N Ruperto, Olga Vougiouka, R. Schneider, C. Wouters, Ekaterina Alexeeva, J. B. Kuemmerle-Deschner, Elie Haddad
Publikováno v:
Annals of the Rheumatic Diseases. 75:401.2-402
Background The main therapeutic goals that can determine success of biologic treatment in systemic juvenile idiopathic arthritis (SJIA) include achieving and maintaining clinical remission, controlling disease activity and tapering corticosteroids (C
Publikováno v:
Annals of the Rheumatic Diseases. 72:A131.2-A131
Background Treat-to-target strategies require instruments for valid detection of joint inflammation. In clinical practice, Disease Activity Score 28 (DAS28) is often used for this purpose. Patient-derived joint counts are a potential alternative for
Autor:
Laura C. Coates, J. Eells, Joseph F. Merola, B. Ink, Richard B. Warren, Laure Gossec, I.B. McInnes, Jason Coarse, Deepak Assudani, Christopher T. Ritchlin
Publikováno v:
Annals of the Rheumatic Diseases. 80:779-780
Background:Bimekizumab (BKZ), a monoclonal antibody inhibitor of interleukin (IL)-17A and IL-17F, demonstrated clinical improvements in joint and skin outcomes up to 108 weeks (wks) in patients (pts) with active psoriatic arthritis (PsA).1,2Objective
Autor:
Gabriel Contreras, David M. Roth, Frédéric Houssiau, M. Okily, Paula S. Curtis, Anuradha Madan, Richard Furie, Angela Jones-Leone, Brad H. Rovin
Publikováno v:
Annals of the Rheumatic Diseases. 80:591-592
Background:BLISS-LN (GSK Study BEL114054; NCT01639339), the largest lupus nephritis (LN) study to date, showed that intravenous (IV) belimumab (BEL) + standard therapy (ST) improved outcomes compared with ST alone in patients (pts) with active LN.1Ob
Autor:
T. Holzkaemper, T. Truer, William Tillett, V. Navarro-Compán, Nicola Booth, J. Hill, Ennio Lubrano
Publikováno v:
Annals of the Rheumatic Diseases. 80:1307-1308
Background:Limited real world (RW) data are available for IL-17A blocker ixekizumab (Ixe), approved for psoriatic arthritis (PsA) in EU Feb 2018.Objectives:Describe RW outcomes for PsA patients (pts) receiving Ixe.Methods:Cross-sectional, observation
Autor:
Proton Rahman, I. McInnes, A. Kollmeier, S. Sheng, E. C. Hsia, Prasheen Agarwal, Christopher T. Ritchlin, X. L. Xu, M. Shawi, B. Zhou, P S Helliwell, P. Ramachandran, Alice B. Gottlieb, P. J. Mease, W. H. Boehncke, S. Kafka
Publikováno v:
Annals of the Rheumatic Diseases. 80:1300-1301
Background:DISCOVER 1 & 2, two double-blind, phase-3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs placebo (PBO) in signs and symptoms of PsA, with good tolerability, at we